Document is current
Any future updates will be listed below
-
Authors
Maas, Lieke https://orcid.org/0000-0002-0032-0712
Raskin, Nele https://orcid.org/0000-0001-9564-5087
van Onna, Marloes https://orcid.org/0000-0001-5535-3119
Cornelissen, Dennis https://orcid.org/0000-0003-3977-580X
Bours, Sandrine
van der Weijden, Trudy https://orcid.org/0000-0002-7469-3781
van den Bergh, Joop P. https://orcid.org/0000-0003-3984-2232
van Oostwaard, Marsha https://orcid.org/0000-0002-2643-1592
Wyers, Caroline E. https://orcid.org/0000-0001-7662-3990
Hiligsmann, Mickaël https://orcid.org/0000-0003-4274-9258
Boonen, Annelies https://orcid.org/0000-0003-0682-9533
-
Funding
Funding for this research was provided by:
ZonMw research line Rational Pharmacotherapy (848016001.)
- License Information
-
More Information
Article History
Received: 1 May 2023
Accepted: 1 September 2023
First Online: 21 September 2023
Declarations
:
: The department of Marloes van Onna has received consultancy fees from Novartis, Pfizer, and Galapagos and a research grant from Pfizer. The department of Annelies Boonen has received consultancy fees from AbbVie, Novartis, and Galapagos. Mickaël Hiligsmann has received research grants paid to his institution by Amgen, Radius Health, and ViiV Healthcare, and consultancy fees from UCB. The department of Joop P. van den Bergh has received consultancy fees from UCB and Amgen. Dennis Cornelissen, Nele Raskin, Marsha van Oostwaard, Caroline E. Wyers, Trudy van der Weijden, Sandrine Bours, and Lieke Maas declare no conflicts of interest.
